February 28, 2018

National Comprehensive Cancer Network (NCCN Compendium®)
Joan McClure, MS, Sr. Vice President, Clinical Information & Publications
275 Commerce Drive, Suite 300
Fort Washington, PA 19034

Dear Ms. McClure,

The enclosed materials are being provided for your information in reference to the IMLYGIC® (talimogene laherparepvec) NCCN Compendium® monograph regarding recently released data on the use of IMLYGIC® (talimogene laherparepvec) in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.

Enclosed, please find the following:

- Summary of Request
- IMLYGIC® (talimogene laherparepvec) US Prescribing Information, Amgen Inc. (v3 08/2017)
- IMLYGIC® (talimogene laherparepvec) Medication Guide, Amgen Inc. (v2 03/2017)

Amgen is providing you with the attached reprint. Please note that if you are a covered recipient as defined by the Affordable Care Act (ACA), Amgen’s cost to obtain such reprint may need to be disclosed and reported in accordance with the requirements under the ACA, state law, and related disclosure obligations by Amgen. If you are a non-covered
recipient requesting information on behalf of or for the benefit of a covered recipient (physician or teaching hospital), the same requirements may apply.

Amgen recommends the use of its products only in accordance with the FDA-approved Prescribing Information (package insert). Please refer to the IMLYGIC® (tлимоген laherparepvec) full Prescribing Information and Medication Guide included in this submission for approved product labeling and important safety information.

Should you have any questions or require additional materials, please feel free to contact me directly at (805) 313-2833. Thank you in advance for your prompt attention to this matter.

Sincerely,

[Signature]

George Jaresko, PharmD
Director, Medical Information
gjaresko@amgen.com